Pharmacyclics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Sunnvale CA United States (1991)
Status: Acquired by AbbVie (2015)

Organization Overview

First Clinical Trial
1998
NCT00003563
First Marketed Drug
2013
ibrutinib (imbruvica)
First NDA Approval
2013
ibrutinib (imbruvica)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PHARMACYCLICS INC | Pharmacyclics LLC. | PHARMACYCLICS LLC | Pharmacyclics LLC an AbbVie Company | Pharmacyclics Switzerland GmbH